Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.

Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests ...
MedPage Today

Next-Generation Sequencing on Fine Needle Aspirate Biopsies: Diagnostic and Therapeutic Utility for Metastatic Prostate Cancer

"In our study, we showed that fine needle aspiration (FNA) biopsy material can be a good source for next-generation sequencing (NGS) for patients with metastatic prostate cancer. Based on these ...

Pangea Laboratory and Gene Solutions Establish Strategic Collaboration to Advance Cancer Diagnostics in the United States

Pangea Laboratory, a CLIA-certified, CAP-accredited leader in Next-Generation Sequencing (NGS) and molecular diagnostic validation and innovation, today announced a strategic collaboration with Gene ...
Labroots

Advancing Cancer Research with Next-Generation Sequencing: Custom Panels, Liquid Biopsy, and Methylation Profiling

Advances in next-generation sequencing (NGS) and synthetic DNA technologies are reshaping oncology research by enabling earlier cancer detection, more accurate biomarker discovery, and sensitive ...
Nasdaq

Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology

Roche's innovative sequencing by expansion (SBX) technology represents a leap forward in next-generation sequencing (NGS), which is playing a vital role in decoding complex diseases like cancer, ...
News-Medical.Net on MSN

MD Anderson and SOPHiA GENETICS join forces to accelerate data-driven cancer care

The University of Texas MD Anderson Cancer Center and SOPHiA GENETICS today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and ...
MedPage Today

Next-Gen Sequencing in NSCLC: What Works and What Lies Ahead

The ongoing Italian clinical and research FPG500 program is designed to tailor matched targeted therapies (MTTs) based on "biomarkers predictive of response identified by comprehensive genome profiling ...